CannIntelligence.com provides independent, in-depth regulatory and market data and intelligence for the global cannabis and cannabinoid sector.
LATEST ALERTS
View all Cannabis and cannabinoids in Brazil
Regulatory reports
Comprehensive legal reports outlining how the sector is regulated, interpretation of the laws and relevant bodies
Regulatory databases
Regularly updated global regulations currently in place, compiled into easy-to-read maps and tables
New trial available: Click on any alert below and access our regulatory alerts and get timely notifications sent to your inbox for 7 days.
Daily news alerts
Our legal experts track the evolving regulation around the cannabinoid and cannabis sector on a daily basis. These alerts are then compiled into our Round-up section.
22nd March 2023
Brazil: Yesterday, 21st March, the Superior Court of Justice published the decision that it falls within the court’s jurisdiction to decide whether hemp can be cultivated for medical, pharmaceutical and industrial purposes. This is in order to avoid different decisions on the same matter. All lawsuits related to hemp cultivation will be suspended, and the court’s decision, which could take at least a year to be made, will be binding.20th February 2023
- Brazil: The Federal Court of Florianópolis, a city in the south of the country, has granted judicial authorisation to a patient association for the cultivation of medical cannabis and the production of cannabis oil for the treatment of its patients, press reports. It is the third association to receive a judicial authorisation for the cultivation and commercialisation of medical cannabis products.
1st February 2023
23rd January 2023
Brazil: The new health minister, Nísia Trindade, has supported medical cannabis and CBD use on national television, press reports. “There is a lot of scientific evidence, and several countries around the world use it for treatments for epilepsy, Alzheimer’s and other health problems. We need the scientific evidence, the dialogue with society, to break through the prejudices and care, which is our keyword,” Trindade said.
19th December 2022
- Brazil: The National Public Health Surveillance Agency (Anvisa) has authorised cannabis cultivation for scientific research purposes. The authorisation was granted to a university to conduct pre-clinical research to evaluate the safety and efficacy of phytocannabinoid combinations in neurological and psychiatric disorders. It is the first time the authority has allowed cultivation of cannabis for research purposes.
7th December 2022
Brazil: The National Public Health Surveillance Agency (Anvisa) has authorised the importation, distribution and sale of two new CBD oils: Canabidiol Hearst 200 mg/ml and Alpha Pharma 200 mg/ml.
29th November 2022
Brazil: The National Public Health Surveillance Agency (Anvisa) has authorised Canabidiol Ease Labs 100 mg/ml to be manufactured in Brazil in the form of a solution for oral use. The agency has already approved 23 cannabis-derived products.
18th November 2022
- Brazil: The National Health Surveillance Agency (Anvisa) has authorised the importation of CBD flowers for medical purposes by an individual, press reports. It is the first time that the agency has authorised the importation of raw cannabis.
31st October 2022
- Brazil: The candidate from the left-wing Workers' Party (PT), Luis Inácio Lula da Silva, won the presidential elections with 50.9% of the votes. His government programme does not address cannabis, but supports a new drug policy focused on risk reduction and prevention. Lula remained neutral about legalisation for medical and recreational purposes, while his vice-president, Geraldo Alckmin, appears favourable to medical legalisation.
25th October 2022
Brazil: The Federal Council of Medicine (CFM) has suspended a resolution restricting medical prescription of CBD after the Federal Public Prosecutor’s Office announced an investigation into its legality. The CFM left open a public consultation reviewing the resolution, which is due to end on 23rd December.
21st October 2022
- Brazil: After issuing a controversial resolution restricting the prescription of CBD for medical use, the Federal Council of Medicine announced that it will receive public contributions with the aim of reviewing the new resolution. Comments can be submitted online between 24th October and 23rd December.
